Author

Nina Prokoph

German Cancer Research CenterORCID 0000-0002-6429-9895Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Research Focus:dimensionality reduction· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Afzal P SyediD· 1 shared Anja Baumann· 1 shared Bengt HallbergiD· 1 shared Charlotte Barrett· 1 shared Christopher Steel· 1 shared Emily R. JamesiD· 1 shared Ezgi SeniD· 1 shared G. A. Amos BurkeiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioinformatics

Afzal P SyedORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Disagreement between demultiplexing methods reveals structured cell quality gradients in multiplexed single-cell data

Ezgi Sen, Simon Steiger, Mislav Bašić, Nina Prokoph, Afzal P Syed, Isabelle Seufert, Usama‐Ur Rehman, Sabrina Schumacher, Anja Baumann, Michaela Feuring‐Buske, Niels Weinhold, Michael Lübbert, Hartmut Döhner, Konstanze Döhner, Marc Steffen Raab, , Karsten Rippe

This paper introduces Split-flow, a pipeline that uses concordance between demultiplexing methods to classify cell quality in multiplexed single-cell data, revealing structured quality gradients.

bioRxiv · May 13, 2026 · PreprintBioinformatics

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma

Perla Pucci, Charlotte Barrett, Ricky M. Trigg, Jamie D. Matthews, Marcus Borenäs, Michaela Schlederer, Leila Jahangiri, Lucy Hare, Christopher Steel, Emily R. James, Nina Prokoph, Lukas Kenner, Ruth Helen Palmer, Bengt Hallberg, G. A. Amos Burke, Suzanne Dawn Turner

This study identifies FGFR2 as a driver of resistance to lorlatinib in ALK-expressing neuroblastoma and shows that FGFR inhibition synergizes with lorlatinib to improve outcomes.

bioRxiv · Sep 5, 2024 · PreprintCancer Biology